8-K current report · filed Aug 4, 2026

ImmunityBio, Inc. (IBRX) 8-K Current Report: August 4, 2026

Item EX-99.1Item 2.02IBRX overview

Short answer

ImmunityBio, Inc. (IBRX) filed an 8-K current report with the SEC on August 4, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Business update and financial results announced for three and six months ended June 30, 2026.

ImmunityBio, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Business update and financial results announced for three and six months ended June 30, 2026
  • Financial position reported as of June 30, 2026
  • Detailed results and operating developments contained in Exhibit 99.1 press release

Item EX-99.1 · Exhibit EX-99.1

  • Q2 net product revenue $50.7M, up 92% YoY and 15% sequentially, marking eight consecutive quarters of growth
  • First-half net product revenue $94.8M, up 121%, supporting accelerating ANKTIVA commercialization
  • GAAP net loss $230.4M versus $92.6M, driven largely by non-cash liability fair-value losses
  • Adjusted net loss improved to $81.0M from $89.9M, indicating better underlying operating performance
  • Cash, cash equivalents, and marketable securities $357.4M; regulatory catalysts include January 6, 2027 FDA action date

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other ImmunityBio, Inc. 8-K filings

Get the next IBRX 8-K as it lands

Follow IBRX for push alerts, or ask the research agent what this filing means.